Home » Posts tagged 'ed lee'

Tag Archives: ed lee

Advanced Oncotherapy (AVO) Chief Ops Officer Ed Lee Q&A with Directors Talk

Advanced Oncotherapy plc (LON:AVO) Chief Operating Officer Ed Lee talks to DirectorsTalk about his background, what that experience brings to AVO and how that knowledge can translate into shareholder value. Transcript below or read on the Directors Talk website here

Q1: Ed, thank you for taking time to speak with us. I understand you joined Advanced Oncotherapy earlier this year?
A1: Thank you for the opportunity to engage with your readers. Yes, I joined AVO in February and have been busy getting to know the company, its culture, personnel, and, of course, the LIGHT system, while helping drive our production priorities forwards.

Q2: Is that your background then, in production?
A2: Yes it is. I worked in senior management production roles with the likes of Meggitt and Northrup Grumman for over 10 years, before joining Optivus Proton Therapy in 2011, where I’ve been since. At Optivus I had dual responsibility for production and for client-facing tasks, such as installation and on-going system servicing.

Q3: Can you tell us a little more about this experience and why it is relevant to AVO?
A3: One of the key crossovers from my time at companies in the aerospace & defence industry is the critical nature of their systems. Quality has to be guaranteed, given the absolute requirement to avoid failures with potentially catastrophic consequences. The same is true of Optivus and all proton therapy businesses, albeit in a more directly relevant manner where patient care is absolutely paramount.

Q4: For those who don’t know, can you explain what Optivus is and does?
A4: Of course. Optivus was the pioneer of proton therapy in the 80’s, setting up the first hospital-based proton treatment and research centre at Loma Linda in California. Today, Optivus has two key products: their own proton therapy system, which is analogous to the hardware of LIGHT, although not a linear accelerator, and a treatment planning system i.e. the computer software and hardware that controls all patient treatment (analogous to LIGHT’s patient treatment systems).

That centre has now treated more than 20,000 cancer patients over 27 years, which is more than any other. That experience, through helping to run a 4 treatment room facility, can translate directly into AVO’s commercial operations.

LIGHT itself is a turn-key solution, in that it provides everything a hospital or clinic would require. My background with Optivus gives me insight into every step of the production process and LIGHT’s clinical application.

Q5: Ed will you explain further how that experience can benefit AVO?
A5: In driving improvements in manufacturing reliability, such as in on-time delivery, for example. On-time delivery relies on enhancing the strength of the production process to reduce occurrence of faulty goods and by executing project plans on time and on budget. This comes about from working closely alongside different departments, establishing the right work culture and employing great people.

All this should lead to an efficient and reliable production process and an ability to offer excellent customer service.

Q6: And is your educational background in a discipline related to manufacturing?
A6: It is, yes. I trained as a mechanical engineer.

Q7: So your focus is on the design and implementation of new machines and systems?
A7: It is to a great extent, but not completely so. For example, I have also worked on the financial analysis and cash flow modelling of new products.

Q8: How is that relevant to what you are doing now?
A8: It’s essential to maintain a financial perspective on the whole of the manufacturing and client servicing process. AVO’s shareholders are expecting a return on their investment and it is my responsibility to help ensure that that happens.

To put it another way, everything that’s done by our scientists and engineers will be financially sound.

But it’s important not to forget that we’re in the business of treating cancer. Like many others, my own family has had to cope with this disease and we have personally benefited from proton therapy.

Q9: And what progress can you flag to AVO’s shareholders?
A9: We’ve already hit a number of the key targets in our project timeline: the proton beam through the RFQ, delivery of CCL units, receipt of our unique ionisation chamber and, just recently, successful integration of and beam firing through the first Side Coupled Drift Tube Linac (“SCDTL”) module.

LIGHT has been designed to be the only proton therapy system on the market that can be mass produced, thereby maximising our commercial opportunities. To do that, we have to make sure there is robustness in our design and repeatability in our manufacturing process.

Q10: Is that readily achievable?
A10: No, it isn’t. But it comes from having an overview of the whole manufacturing and client-servicing process, which I have, and by working with all relevant stakeholders, such as our suppliers, manufacturing partners, customers and, of course, our R&D team.

Q11: How much of a benefit is it to AVO to be able to draw on the knowledge of your scientists and engineers in Geneva?
A11: It’s hugely beneficial to AVO. My challenge is helping to ensure the intellectual property within AVO gets converted into shareholder value. It’s one I am relishing and am confident we can achieve as a team.

Advanced Oncotherapy (AVO) – Additional financing agreement and new appointment

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces it has made further progress in attracting personnel at the forefront of their field and additional financing.

Additional Financing

Advanced Oncotherapy announces, that on 12 June 2017, it has entered into a further loan agreement with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited and has drawn down an additional £1.5 million. This brings the total financing from Blackfinch to £6.5 million and follows two prior agreements, announced on 27 March 2017 and 25 April 2017. Unlike the Prior Agreements, this loan is secured against anticipated cash receivables.

Terms of the Loan Agreement

·     1 year maximum loan term, with term commencing on 24 March 2017

·     Principal of £1.5m

·     The £1.5m has been secured on known cash receivables and will be repaid upon receipt of these monies

·     Annual interest rate of 12%

·     500,000 warrants with 100p exercise price, exercisable for five years

·     This agreement does not change the loan security outlined in the announcements of the Prior Agreements on the first £5 million drawn down from Blackfinch

New appointment

The Company announces the appointment of Ed Lee as Chief Operating Officer with immediate effect. 

Ed joined the Company on 13 February 2017 and will be responsible for spearheading the operations and project management of the LIGHT system and, critically, for bringing the LIGHT system to market. Ed will not be taking a position on the Board.

A mechanical engineer by background, Ed has gained progressive responsibilities in manufacturing and operations over the last 23 years and brings a wealth of knowledge to Advanced Oncotherapy. His experience lies in new product development, supply chain management, project management, cost reduction, operational management and value engineering; such as launching new products on time and on budget and improving the robustness of the production process.

He is skilled in leading and working closely with multiple teams to realize stakeholder interests: technical/R&D, quality, regulatory, procurement, sales and finance.

Previously, Ed was the Director of Production & Field Service at Optivus Proton Therapy Inc, where he was responsible for all on-going and new product development aspects of production and on-going servicing of the company’s customers’ proton therapy technology. His manufacturing and operational experiences span several industries and sectors, including automotive, aerospace & defence, nuclear and medical devices.  Aside from Proton Treatment Systems, he has led teams that have successfully launched new products where regulatory requirements are extremely stringent such as on military jets, military ships, space satellites, submarines, and nuclear power plants.

Commenting on the appointment, Nicolas Serandour, CEO of Advanced Oncotherapy said: “Ed’s background gives him excellent insight into every step of the production and clinical-user processes for our LIGHT system. He will be responsible for leading and driving the team to develop and produce the LIGHT system in an efficient and timely manner as demonstrated consistently in his previous roles. He is already a great asset to the team.”

Commenting on his appointment, Ed Lee, COO of Advanced Oncotherapy said: “One of my key objectives at Advanced Oncotherapy is to help ensure the considerable value of intellectual property associated with LIGHT is translated into profitable operations. It’s one I am relishing and am confident of achieving as a team. What the Company is trying to achieve – making proton therapy more affordable and clinically better, thereby saving lives – is my foremost incentive.” 

Advanced Oncotherapy Plc


Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO

Stockdale Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten

Tel: +44 20 7601 6100

Stifel Nicolaus Europe (Joint Broker)

Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.